Key statistics
On Thursday, Nuvation Bio Inc (NUVB:NYQ) closed at 2.95, -29.08% below its 52-week high of 4.16, set on Mar 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.00 |
---|---|
High | 3.04 |
Low | 2.92 |
Bid | 2.85 |
Offer | 3.11 |
Previous close | 2.90 |
Average volume | 1.57m |
---|---|
Shares outstanding | 334.78m |
Free float | 243.64m |
P/E (TTM) | -- |
Market cap | 970.86m USD |
EPS (TTM) | -2.11 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 00:00 BST.
More ▼
- Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
- Nuvation Bio to Present at the Cantor Global Healthcare Conference
- Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
- Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib